TALi appoints new CEO
TALi Health is delighted to announce that Dr Mary Beth Brinson has been appointed as the CEO of TALi Health.
Read more
TALi Digital (ASX: TD1)
Investing in the future of digital therapeutics and innovation.
Wholly invested in TALi Health.
We are 100% invested in TALi Health who are developing evidence-based tools to measure, assess and improve attention.
TALi has built platform technology, with the initial applications targeting cognitive attention skills during early childhood. The first to market attention screening ('DETECT') and training ('TRAIN') programs are complementary to existing diagnosis and therapy placing TALi at the forefront of early intervention for attention related conditions.
A continuous innovation focus sees TALi deliver ongoing product developments in this space, which are underpinned by a core research program exploring additional applications.
